NCT01223911 - A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

InflammationRheumatoid Arthritis

Interventions

DRUG

NNC 0151-0000-0000

Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period

DRUG

placebo

Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period

Trial Locations (16)

1027

Novo Nordisk Investigational Site, Budapest

2000

Novo Nordisk Investigational Site, Frederiksberg

8600

Novo Nordisk Investigational Site, Silkeborg

400006

Novo Nordisk Investigational Site, Cluj-Napoca

520064

Novo Nordisk Investigational Site, Sfântu Gheorghe

600114

Novo Nordisk Investigational Site, Bacau

128 50

Novo Nordisk Investigational Site, Prague

15-879

Novo Nordisk Investigational Site, Bialystok

82-300

Novo Nordisk Investigational Site, Elblag

31-637

Novo Nordisk Investigational Site, Krakow

61-218

Novo Nordisk Investigational Site, Poznan

011172

Novo Nordisk Investigational Site, Bucharest

020475

Novo Nordisk Investigational Site, Bucharest

ST6 7AG

Novo Nordisk Investigational Site, Burslem

NE1 4LP

Novo Nordisk Investigational Site, Newcastle upon Tyne

SA6 6NL

Novo Nordisk Investigational Site, Swansea